These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 21388309)

  • 1. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
    Menne J; Izzo JL; Ito S; Januszewicz A; Katayama S; Chatzykirkou C; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G; Haller H;
    J Hypertens; 2012 Apr; 30(4):811-8; discussion 818. PubMed ID: 22418908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
    Menne J; Ritz E; Ruilope LM; Chatzikyrkou C; Viberti G; Haller H
    J Am Heart Assoc; 2014; 3(2):e000810. PubMed ID: 24772521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 6. Olmesartan, microalbuminuria, and type 2 diabetes.
    Yudkin JS; Lehman R
    N Engl J Med; 2011 Jun; 364(23):2260; author reply 2262-3. PubMed ID: 21651401
    [No Abstract]   [Full Text] [Related]  

  • 7. Olmesartan, microalbuminuria, and type 2 diabetes.
    Lammert A; Krämer BK; Krüger B
    N Engl J Med; 2011 Jun; 364(23):2261; author reply 2262-3. PubMed ID: 21651399
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for the development of microalbuminuria and interaction with renal function.
    Chatzikyrkou C; Menne J; Izzo J; Viberti G; Rabelink T; Ruilope LM; Rump C; Mertens PR; Haller H
    J Hypertens; 2017 Dec; 35(12):2501-2509. PubMed ID: 29035939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olmesartan, microalbuminuria, and type 2 diabetes.
    Fioretto P; Mauer M
    N Engl J Med; 2011 Jun; 364(23):2260-1; author reply 2262-3. PubMed ID: 21651400
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
    Imai E; Chan JC; Ito S; Yamasaki T; Kobayashi F; Haneda M; Makino H;
    Diabetologia; 2011 Dec; 54(12):2978-86. PubMed ID: 21993710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Ritz E; Viberti GC; Ruilope LM; Rabelink AJ; Izzo JL; Katayama S; Ito S; Mimran A; Menne J; Rump LC; Januszewicz A; Haller H
    Diabetologia; 2010 Jan; 53(1):49-57. PubMed ID: 19876613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
    Imai E; Haneda M; Yamasaki T; Kobayashi F; Harada A; Ito S; Chan JC; Makino H
    Hypertens Res; 2013 Dec; 36(12):1051-9. PubMed ID: 24026038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
    Iseki K; Arima H; Kohagura K; Komiya I; Ueda S; Tokuyama K; Shiohira Y; Uehara H; Toma S;
    Nephrol Dial Transplant; 2013 Jun; 28(6):1579-89. PubMed ID: 23355629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
    Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
    Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study.
    Schmieder RE; Bramlage P; Haller H; Ruilope LM; Böhm M;
    Medicine (Baltimore); 2016 Apr; 95(15):e3122. PubMed ID: 27082551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.